JPRN-jRCT1010230005招募中Unknown
ong-term follow-up study after 'Treatment of lumbar canal stenosis with a combination of ultra-purified, allogenic, bone marrow-derived, mesenchymal stem cells (REC) and in situ-forming gel: a multicentre, prospective, double blind, randomised, controlled trial'
Hideki Sudo0 个研究点目标入组 45 人开始时间: 2023年4月29日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Willingness to provide written informed consent, fill in all necessary questionnaires, and return for follow-up.
排除标准
- •Any other reason judged by an investigator or clinical trial doctor that renders the candidate unsuitable for this clinical trial.
研究者
相似试验
进行中（未招募）
1 期
A long-term follow-up study for patients treated with Galapagos CAR T cell therapiesRelapsed/refractory B-Cell non-Hodgkin lymphoma, Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Relapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code: 10051812Term: Small cell lymphocytic lymphoma Class: 10029104MedDRA version: 20.0Level: HLGTClassification code: 10025320Term: Lymphomas non-Hodgkin's B-cell Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104CTIS2023-510173-34-00Galapagos300
尚未招募
不适用
ong term follow up after operative treatment of ulnar collateral ligament injuries the thumbSkier's thumbulnar collateral ligament injury1004323710005944NL-OMON40760Sint Elisabeth Ziekenhuis100
进行中（未招募）
1 期
ong-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapieson-small cell lung cancer (NSCLC), Multiple Myeloma & other indications, Synovial sarcoma, Myxoid/round cell liposarcoma (MRCLS)MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10073137Term: Myxoid liposarcoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042863Term: Synovial sarcoma Class: 100000004864CTIS2024-513033-21-00Adaptimmune LLC76
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcomaMultiple myelomaNon-small cell lung cancerMyxoid liposarcomaMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-NLGlaxoSmithKline research & development Ltd.171
进行中（未招募）
1 期
Adoptive cell therapy LTFU studySynovial sarcoma, Non-small cell lung cancer (NSCLC), Myxoid/round cell liposarcoma (MRCLS), Multiple Myeloma & other indicationsMedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073137Term: Myxoid liposarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004888-31-FRGlaxoSmithKline Research & Development Ltd171